Affibody appoints Dr. Nikolai Brun as CMO
August 20, 2021
Solna, Sweden, August 23, 2021. Affibody AB (“Affibody”), a company developing innovative bi- and multi-specific next generation biopharmaceuticals, today announced it has appointed Dr. Nikolai Brun as CMO. Dr. Brun will join the Affibody leadership team and will be responsible for the clinical safety, development and operations functions as well as regulatory affairs.
Nikolai Brun has held a variety of clinical development leadership positions within the pharmaceutical industry over the last 20 years. The experience has been gained at both larger and smaller organizations, such as Novo Nordisk, Genmab and Genzyme as well as the Danish Medicines Agency.
“We are pleased to welcome Nikolai to Affibody. His substantial experience from clinical development and regulatory affairs is very appreciated as we are initiating multiple new studies. The experience he has from global clinical studies together with collaborators is also very valuable to us as we progress our collaboration with Inmagene further into the clinic,” said David Bejker, CEO.
Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.
The company operates a focused experimental medicine model and currently has two clinical stage programs. The first is izokibep that targets autoimmune diseases. The second program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
Affibody AB is a holding of Patricia Industries.
Further information can be found at: www.affibody.com